Clinical utility of reverse phase protein array for molecular classification of breast cancer

被引:14
|
作者
Negm, Ola H. [1 ,2 ]
Muftah, Abir A. [3 ,4 ,5 ]
Aleskandarany, Mohammed A. [3 ,4 ]
Hamed, Mohamed R. [1 ,2 ]
Ahmad, Dena A. J. [3 ,4 ]
Nolan, Christopher C. [3 ,4 ]
Diez-Rodriguez, Maria [3 ,4 ]
Tighe, Patrick J. [1 ]
Ellis, Ian O. [3 ,4 ]
Rakha, Emad A. [3 ,4 ]
Green, Andrew R. [3 ,4 ]
机构
[1] Univ Nottingham, Sch Life Sci, Immunol, Nottingham NG7 2UH, England
[2] Mansoura Univ, Fac Med, Dept Med Microbiol & Immunol, Mansoura, Egypt
[3] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Dept Histopathol, Nottingham NG7 2UH, England
[4] Nottingham Univ Hosp NHS Trust, City Hosp Nottingham, Dept Histopathol, Nottingham, England
[5] Benghazi Univ, Fac Med, Dept Pathol, Benghazi, Libya
关键词
Reverse phase protein array; Formalin-fixed and paraffin-embedded; Protein extraction; Breast cancer; Nottingham prognostic index plus; PARAFFIN-EMBEDDED TISSUE; FORMALIN-FIXED TISSUES; CELL SIGNALING ANALYSIS; PERSONALIZED THERAPY; MICROARRAYS; IDENTIFICATION; SENSITIVITY; PROTEOMICS; NETWORK; SAMPLES;
D O I
10.1007/s10549-015-3654-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Reverse Phase Protein Array (RPPA) represents a sensitive and high-throughput technique allowing simultaneous quantitation of protein expression levels in biological samples. This study aimed to confirm the ability of RPPA to classify archival formalin-fixed paraffin-embedded (FFPE) breast cancer tissues into molecular classes used in the Nottingham prognostic index plus (NPI+) determined by immunohistochemistry (IHC). Proteins were extracted from FFPE breast cancer tissues using three extraction protocols: the Q-proteome FFPE Tissue Kit (Qiagen, Hilden, Germany) and two in-house methods using Laemmli buffer with either incubation for 20 min or 2 h at 105 degrees C. Two preparation methods, full-face sections and macrodissection, were used to assess the yield and quality of protein extracts. Ten biomarkers used for the NPI+ (ER, PgR, HER2, Cytokeratins 5/6 and 7/8, EGFR, HER3, HER4, p53 and Mucin 1) were quantified using RPPA and compared to results determined by IHC. The Q-proteome FFPE Tissue Kit produced significantly higher protein concentration and signal intensities. The intra-and inter-array reproducibility assessment indicated that RPPA using FFPE lysates was a highly reproducible and robust technique. Expression of the biomarkers individually and in combination using RPPA was highly consistent with IHC results. Macrodissection of the invasive tumour component gave more reliable results with the majority of biomarkers determined by IHC, (80 % concordance) compared with full -face sections (60 % concordance). Our results provide evidence for the technical feasibility of RPPA for high throughput protein expression profiling of FFPE breast cancer tissues. The sensitivity of the technique is related to the quality of extracted protein and purity of tumour tissue. RPPA could provide a quantitative technique alternative to IHC for the biomarkers used in the NPI+.
引用
收藏
页码:25 / 35
页数:11
相关论文
共 50 条
  • [1] Clinical utility of reverse phase protein array for molecular classification of breast cancer
    Ola H. Negm
    Abir A. Muftah
    Mohammed A. Aleskandarany
    Mohamed R. Hamed
    Dena A. J. Ahmad
    Christopher C. Nolan
    Maria Diez-Rodriguez
    Patrick J. Tighe
    Ian O. Ellis
    Emad A. Rakha
    Andrew R. Green
    Breast Cancer Research and Treatment, 2016, 155 : 25 - 35
  • [2] The Merits of Reverse Phase Protein Array for Molecular Classification of Breast Cancer
    Negm, O. H.
    Muftah, A. A.
    Aleskandarany, M. A.
    Hamed, M. R.
    Ahmad, D. A. J.
    Nolan, C. C.
    Rodriguez, M. D.
    Tighe, P. J.
    Ellis, I. O.
    Rakha, E. A.
    Green, A. R.
    JOURNAL OF PATHOLOGY, 2016, 240 : 15 - 15
  • [3] Reverse phase protein array in breast cancer classification.
    Hennessy, BT
    Lu, Y
    Tibes, R
    Gozalez-Angulo, AM
    Hortobagyi, GN
    Valero, V
    Mills, GB
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S114 - S115
  • [4] Molecular classification of breast cancers: Clinical utility
    Lamy, P-J
    Romieu, G.
    Rouanet, P.
    Jacot, W.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2010, 34 (01): : 32 - 43
  • [5] Breast Cancer Proteomic Profiling Using Reverse Phase Protein Array (RPPA)
    Negm, O. H.
    Alshareeda, A. T.
    Aleskandarany, M. A.
    Green, A. G.
    Ellis, I. O.
    Rakha, E. A.
    Tighe, P. J.
    JOURNAL OF PATHOLOGY, 2013, 231 : 13 - 13
  • [6] Classification of molecular subtypes of triple-negative breast cancer using reverse phase protein arrays (RPPAs).
    Masuda, Hiroko
    Qi, Yuan
    Liu, Shuying
    Hayashi, Naoki
    Kogawa, Takahiro
    Hortobagyi, Gabriel N.
    Valero, Vicente
    Gonzalez-Angulo, Ana M.
    Ueno, Naoto T.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes
    Masuda, Hiroko
    Qi, Yuan
    Liu, Shuying
    Hayashi, Naoki
    Kogawa, Takahiro
    Hortobagyi, Gabriel N.
    Tripathy, Debu
    Ueno, Naoto T.
    ONCOTARGET, 2017, 8 (41) : 70481 - 70495
  • [8] Utility of Reverse-Phase Protein Array for Refining Precision Oncology
    Masuda, Mari
    Yamada, Tesshi
    REVERSE PHASE PROTEIN ARRAYS: FROM TECHNICAL AND ANALYTICAL FUNDAMENTALS TO APPLICATIONS, 2019, 1188 : 239 - 249
  • [9] Protein biomarker signature for risk classification of hormone receptor positive breast cancer identified by reverse phase protein array based tumor profiling
    Sonntag, J.
    Bender, C.
    Aulmann, S.
    Von der Heyde, S.
    Burwinkel, B.
    Wiemann, S.
    Beissbarth, T.
    Sinn, H. P.
    Schneeweiss, A.
    Korf, U.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S212 - S212
  • [10] Molecular signatures of breast cancer: What clinical utility?
    Delaloge, Suzette
    Saghatchian, Mahasti
    Ghouadni, Amal
    Fekih, Mahmoud
    Andre, Fabrice
    BULLETIN DU CANCER, 2015, 102 (06) : S102 - S105